Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)

INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) and non-IPF, progressive fibrotic interstitial lung diseases (PF-ILD), are associated with a progressive loss of lung function and a poor prognosis. Treatment with antifibrotic agents can slow, but not halt, disease progression, and treatment discont...

Descripción completa

Detalles Bibliográficos
Autores principales: Corte, Tamera J, Lancaster, Lisa, Swigris, Jeffrey J, Maher, Toby M, Goldin, Jonathan G, Palmer, Scott M, Suda, Takafumi, Ogura, Takashi, Minnich, Anne, Zhan, Xiaojiang, Tirucherai, Giridhar S, Elpers, Brandon, Xiao, Hong, Watanabe, Hideaki, Smith, R Adam, Charles, Edgar D, Fischer, Aryeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Interstitial Lung Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718498/
https://www.ncbi.nlm.nih.gov/pubmed/34969771
http://dx.doi.org/10.1136/bmjresp-2021-001026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718498/
https://www.ncbi.nlm.nih.gov/pubmed/34969771
http://dx.doi.org/10.1136/bmjresp-2021-001026

Ejemplares similares